Influence of SULT1A1 genetic variation on age at menopause, estrogen levels, and response to hormone therapy in recently postmenopausal white women.
Onset and symptoms of menopause, and response to hormone therapy (HT) show large interindividual variability. SULT1A1 encodes for a highly expressed enzyme that metabolizes estrogens. We evaluated the relationship between genetic variation in SULT1A1, menopause age, symptoms, and response to HT.



Women enrolled in the Kronos Early Estrogen Prevention Study at Mayo Clinic were randomized to 48 months of treatment with oral conjugated equine estrogen (n = 34), transdermal 17β-estradiol (E2) (n = 33), or placebo (n = 35). Linear regression models and ANOVA were used to test for association of SULT1A1 copy number, rs3760091, rs750155, and rs9282861 (SULT1A12), with age at menopause and symptoms, levels of estrogens (estrone [E1], estrone sulfate [E1S], E2, and estradiol sulfate [E2S]), before and after HT.



SULT1A1 gene copy number affected the minor allele frequency for each single nucleotide polymorphisms tested. Before administration of exogenous hormones, increasing number of G alleles at rs9282861 was associated with earlier age at menopause (P = 0.014), lower frequency of night sweats (P = 0.009), and less severe insomnia (P = 0.046). After 48 months of treatment, SULT1A1 genotype was not associated with the presence of menopausal symptoms. In women randomized to oral conjugated equine estrogen, increasing number of the A allele at rs750155 was associated with lower E1S and E2S (P = 0.004 and 0.017), whereas increasing number of the C allele at rs3760091 was associated with lower E2S/E2 (P = 0.044).



Interindividual variability in onset of menopause and symptoms before initiation of HT is explained in part by genetic variation in SULT1A1 and may represent a step toward individualizing HT treatment decisions.
1Department of Laboratory Medicine and Pathology 2Division of Biomedical Statistics and Informatics 3Department of Molecular Pharmacology and Experimental Therapeutics 4Departments of Surgery and Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN.
Ann M
AM
Moyer
Mariza
M
de Andrade
Richard M
RM
Weinshilboum
Virginia M
VM
Miller
D000279:Administration, Cutaneous; D000328:Adult; D000367:Age Factors; D000483:Alleles; D015239:Arylsulfotransferase / Q000235:genetics*; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004967:Estrogens / Q000008:administration & dosage* / Q000097:blood; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage*; D005260:Female; D014644:Genetic Variation; D006801:Humans; D016014:Linear Models; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D017698:Postmenopause / Q000097:blood / Q000187:drug effects / Q000235:genetics*; D044465:White People / Q000235:genetics*
D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D015239:Arylsulfotransferase; C117544:SULT1A1 protein, human